ʻO ka maʻi ʻai Binge: ʻAe ʻia ka holomua o ka hoʻāʻo ʻana e ka FDA

A HOLD Hoʻokuʻu ʻole 5 | eTurboNews | eTN
i kakauia ma Linda Hohnholz

ʻO Tryp Therapeutics, kahi hui lāʻau lapaʻau e kālele ana i ka hoʻomohala ʻana i nā pūhui psilocybin-based no nā maʻi me ka pono ʻole o ka lāʻau lapaʻau, hoʻolaha i kēia lā i ka loaʻa ʻana o nā leka mai ka US Food and Drug Administration (FDA) e hōʻoia ana i ka hiki o ka Hui ke hoʻomau i kahi hoʻokolohua lapaʻau Phase 2a e loiloi ana i ka. ka hoʻohana ʻana i ka psilocybin synthetic no ka maʻi ʻai nui.

Ua hoʻolaha mua ka hui ma ʻOkakopa 20, 2021 i kahi paʻa lapaʻau i kau ʻia ma ke aʻo ʻana e ka FDA. Ua hāʻawi ka Hui i kahi mea hou e pili ana i ka mea ma Nowemapa 18, 2021 a waiho i kahi hoʻololi i ka FDA no ka noi noiʻi Investigational New Drug (IND) ma Dekemaba 9, 2021. Ma o ka leka i loaʻa i kēia pule, ua wehe ka FDA i ka paʻa lapaʻau a ʻōlelo aku. Tryp hiki ke hoʻomau i ke aʻo ʻana.

Ma ka ʻōlelo ʻana e pili ana i ka hoʻomohala ʻana, ua ʻōlelo ka Pelekikena a me Luna Nui ʻo Greg McKee, "Ua hauʻoli mākou e neʻe i mua me kā mākou Phase 2a hoʻokolohua lapaʻau i ka maʻi ʻai binge ma o kā mākou hui pū ʻana me ke Kulanui o Florida. ʻO kā mākou kamaʻilio me ka FDA ua huahua a ua hoʻomaikaʻi maikaʻi i ka hoʻolālā ʻana o kēia haʻawina. Hōʻike kēia i ka noiʻi lapaʻau lua ma 2021 i loaʻa iā mākou ka ʻae mai ka FDA e hoʻomaka.

<

No ka mea kākau

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...